(Reuters) - Pfizer Inc said two of its anti-fungal drugs, when used together to treat a dangerous systemic fungal infection, failed to meet the main goal of a late-stage trial.
The company tested its treatment Vfend in combination with its other antifungal drug Eraxis in people suffering with invasive aspergillosis, a life-threatening fungal infection that can develop in patients with compromised immune systems.
Eraxis is an injectable drug used to treat Candida and other fungal infections. It was approved five years ago after positive data from a late-stage trial that compared it with the widely used antifungal fluconazole.
The drugs, when used in combination, did show a lower all-cause mortality rate at six weeks compared with treatment with Vfend alone, Pfizer said on Friday. But the difference was not deemed statistically significant.
The safety and tolerability of the combination of Vfend and Eraxis was similar to that of Vfend by itself.
The company tested its treatment Vfend in combination with its other antifungal drug Eraxis in people suffering with invasive aspergillosis, a life-threatening fungal infection that can develop in patients with compromised immune systems.
Eraxis is an injectable drug used to treat Candida and other fungal infections. It was approved five years ago after positive data from a late-stage trial that compared it with the widely used antifungal fluconazole.
The drugs, when used in combination, did show a lower all-cause mortality rate at six weeks compared with treatment with Vfend alone, Pfizer said on Friday. But the difference was not deemed statistically significant.
The safety and tolerability of the combination of Vfend and Eraxis was similar to that of Vfend by itself.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου